Skip to content
2000
image of Hypertension is the Main Vascular Risk Factor for Cognitive Impairment, Microvascular Pathology and Brain Atrophy in Alzheimer’s Disease

Abstract

Introduction

Alzheimer’s Disease (AD) is the commonest pathology underlying dementia, but it frequently coexists with cerebrovascular disease (CVD). Existing literature supports a possible role for vascular risk factors (VRFs), including hypertension, diabetes and dyslipidaemia in AD pathogenesis. This study aims to determine whether VRFs contribute to typical AD pathogenesis or co-morbid CVD in mixed AD.

Methods

Well-characterised probable AD subjects participating in two large clinical trials of Hydromethylthionine were classified into “typical AD” and “mixed” patterns based on FDG-PET images. VRFs, including hypertension, diabetes and dyslipidaemia, and MRI-derived White Matter Hyperintensities (WMHs) and brain fraction (as a measure of brain atrophy) were analysed to investigate the relationship between VRFs and AD subtypes.

Results

Of 794 participants, 533 (67.1%) were classified as typical AD and 261 (32.8%) were classified as mixed. Among VRFs, cardiovascular risks were significantly more frequent in typical AD (59%) than in mixed subtype (47%) ( 0.002).

Discussion

We found that it was mainly hypertension that differed according to subtypes. Although brain atrophy is the main driver of cognitive impairment in patients with AD subtype, the microvascular pathology in the form of WMHs was significantly higher in patients with hypertension, irrespective of subtype.

Conclusion

Although hypertension is the main risk factor for cerebrovascular disease, contrary to our expectation, hypertension is common in typical AD than the mixed subtype, and this association is driven by the hitherto unsuspected contribution of microvascular pathology to cognitive impairment in typical AD.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/car/10.2174/0115672050399596251106033110
2026-01-02
2026-01-12

  • From This Site

    /content/journals/car/10.2174/0115672050399596251106033110
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Kurz A.F. Lautenschlager N.T. The concept of dementia: retain, reframe, rename or replace? Int. Psychogeriatr. 2010 22 1 37 42 10.1017/S1041610209991013 19814839
    [Google Scholar]
  2. Love S. Miners J.S. Cerebrovascular disease in ageing and Alzheimer’s disease. Acta Neuropathol. 2016 131 5 645 658 10.1007/s00401‑015‑1522‑0 26711459
    [Google Scholar]
  3. Tahami Monfared A.A. Byrnes M.J. White L.A. Zhang Q. Alzheimer’s Disease: Epidemiology and clinical progression. Neurol. Ther. 2022 11 2 553 569 10.1007/s40120‑022‑00338‑8 35286590
    [Google Scholar]
  4. Tripathi S.M. Murray A.D. Alzheimer’s Dementia: The emerging role of positron emission tomography. Neuroscientist 2022 28 5 507 519 10.1177/1073858421997035 33660556
    [Google Scholar]
  5. Jack C.R. Jr Bennett D.A. Blennow K. Carrillo M.C. Dunn B. Haeberlein S.B. Holtzman D.M. Jagust W. Jessen F. Karlawish J. Liu E. Molinuevo J.L. Montine T. Phelps C. Rankin K.P. Rowe C.C. Scheltens P. Siemers E. Snyder H.M. Sperling R. Elliott C. Masliah E. Ryan L. Silverberg N. NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018 14 4 535 562 10.1016/j.jalz.2018.02.018 29653606
    [Google Scholar]
  6. Dubois B. Villain N. Frisoni G.B. Rabinovici G.D. Sabbagh M. Cappa S. Bejanin A. Bombois S. Epelbaum S. Teichmann M. Habert M.O. Nordberg A. Blennow K. Galasko D. Stern Y. Rowe C.C. Salloway S. Schneider L.S. Cummings J.L. Feldman H.H. Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group. Lancet Neurol. 2021 20 6 484 496 10.1016/S1474‑4422(21)00066‑1 33933186
    [Google Scholar]
  7. Nelson P.T. Alafuzoff I. Bigio E.H. Bouras C. Braak H. Cairns N.J. Castellani R.J. Crain B.J. Davies P. Tredici K.D. Duyckaerts C. Frosch M.P. Haroutunian V. Hof P.R. Hulette C.M. Hyman B.T. Iwatsubo T. Jellinger K.A. Jicha G.A. Kövari E. Kukull W.A. Leverenz J.B. Love S. Mackenzie I.R. Mann D.M. Masliah E. McKee A.C. Montine T.J. Morris J.C. Schneider J.A. Sonnen J.A. Thal D.R. Trojanowski J.Q. Troncoso J.C. Wisniewski T. Woltjer R.L. Beach T.G. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J. Neuropathol. Exp. Neurol. 2012 71 5 362 381 10.1097/NEN.0b013e31825018f7 22487856
    [Google Scholar]
  8. Weigand A.J. Bangen K.J. Thomas K.R. Delano-Wood L. Gilbert P.E. Brickman A.M. Bondi M.W. Alzheimer’s Disease Neuroimaging Initiative Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity. Brain Commun. 2020 2 1 fcz046 10.1093/braincomms/fcz046 32051933
    [Google Scholar]
  9. Reiss A.B. Montufar N. DeLeon J. Pinkhasov A. Gomolin I.H. Glass A.D. Arain H.A. Stecker M.M. Alzheimer disease clinical trials targeting amyloid. Neurologist 2021 26 2 52 61 10.1097/NRL.0000000000000320 33646990
    [Google Scholar]
  10. Huang L.K. Chao S.P. Hu C.J. Clinical trials of new drugs for Alzheimer disease. J. Biomed. Sci. 2020 27 1 18 10.1186/s12929‑019‑0609‑7 31906949
    [Google Scholar]
  11. Giannakopoulos P. Herrmann F.R. Bussière T. Bouras C. Kövari E. Perl D.P. Morrison J.H. Gold G. Hof P.R. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology 2003 60 9 1495 1500 10.1212/01.WNL.0000063311.58879.01 12743238
    [Google Scholar]
  12. Pasi M. Poggesi A. Pantoni L. The use of CT in dementia. Int. Psychogeriatr. 2011 23 S2 S6 S12 10.1017/S1041610211000950 21729420
    [Google Scholar]
  13. Patel K.P. Wymer D.T. Bhatia V.K. Duara R. Rajadhyaksha C.D. Multimodality imaging of Dementia: Clinical importance and role of integrated anatomic and molecular imaging. Radiographics 2020 40 1 200 222 10.1148/rg.2020190070 31917652
    [Google Scholar]
  14. Kivipelto M. Helkala E.L. Laakso M.P. Hänninen T. Hallikainen M. Alhainen K. Soininen H. Tuomilehto J. Nissinen A. Midlife vascular risk factors and Alzheimer’s disease in later life: Longitudinal, population based study. BMJ 2001 322 7300 1447 1451 10.1136/bmj.322.7300.1447 11408299
    [Google Scholar]
  15. Iadecola C. The pathobiology of vascular dementia. Neuron 2013 80 4 844 866 10.1016/j.neuron.2013.10.008 24267647
    [Google Scholar]
  16. Vijayan M. Reddy P.H. Stroke, vascular Dementia, and Alzheimer’s Disease: Molecular links. J. Alzheimers Dis. 2016 54 2 427 443 10.3233/JAD‑160527 27567871
    [Google Scholar]
  17. Livingston G. Huntley J. Sommerlad A. Ames D. Ballard C. Banerjee S. Brayne C. Burns A. Cohen-Mansfield J. Cooper C. Costafreda S.G. Dias A. Fox N. Gitlin L.N. Howard R. Kales H.C. Kivimäki M. Larson E.B. Ogunniyi A. Orgeta V. Ritchie K. Rockwood K. Sampson E.L. Samus Q. Schneider L.S. Selbæk G. Teri L. Mukadam N. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 2020 396 10248 413 446 10.1016/S0140‑6736(20)30367‑6 32738937
    [Google Scholar]
  18. de la Torre J. The vascular hypothesis of Alzheimer’s disease: A key to preclinical prediction of dementia using neuroimaging. J. Alzheimers Dis. 2018 63 1 35 52 10.3233/JAD‑180004 29614675
    [Google Scholar]
  19. Montero-Odasso M. Ismail Z. Livingston G. One third of dementia cases can be prevented within the next 25 years by tackling risk factors. The case “for” and “against”. Alzheimers Res. Ther. 2020 12 1 81 10.1186/s13195‑020‑00646‑x 32641088
    [Google Scholar]
  20. Garibotto V. Herholz K. Boccardi M. Picco A. Varrone A. Nordberg A. Nobili F. Ratib O. Geneva Task Force for the Roadmap of Alzheimer’s Biomarkers Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol. Aging 2017 52 183 195 10.1016/j.neurobiolaging.2016.03.033 28317648
    [Google Scholar]
  21. Heiss W.D. The additional value of PET in the assessment of cerebral small vessel disease. J. Nucl. Med. 2018 59 11 1660 1664 10.2967/jnumed.118.214270 29959217
    [Google Scholar]
  22. Kerrouche N. Herholz K. Mielke R. Holthoff V. Baron J.C. 18FDG PET in vascular dementia: Differentiation from Alzheimer’s disease using voxel-based multivariate analysis. J. Cereb. Blood Flow Metab. 2006 26 9 1213 1221 10.1038/sj.jcbfm.9600296 16525414
    [Google Scholar]
  23. Mielke R. Pietrzyk U. Jacobs A. Fink G. Ichimiya A. Kessler J. Herholz K. Heiss W. HMPAO SPET and FDG PET in Alzheimer’s disease and vascular dementia: Comparison of perfusion and metabolic pattern. Eur. J. Nucl. Med. 1994 21 10 1052 1060 10.1007/BF00181059 7828614
    [Google Scholar]
  24. Marcus C. Mena E. Subramaniam R.M. Brain PET in the diagnosis of Alzheimer’s disease. Clin. Nucl. Med. 2014 39 10 e413 e426 10.1097/RLU.0000000000000547 25199063
    [Google Scholar]
  25. Bloudek L.M. Spackman D.E. Blankenburg M. Sullivan S.D. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J. Alzheimers Dis. 2011 26 4 627 645 10.3233/JAD‑2011‑110458 21694448
    [Google Scholar]
  26. Kapasi A. DeCarli C. Schneider J.A. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017 134 2 171 186 10.1007/s00401‑017‑1717‑7 28488154
    [Google Scholar]
  27. Gauthier S. Feldman H.H. Schneider L.S. Wilcock G.K. Frisoni G.B. Hardlund J.H. Moebius H.J. Bentham P. Kook K.A. Wischik D.J. Schelter B.O. Davis C.S. Staff R.T. Bracoud L. Shamsi K. Storey J.M.D. Harrington C.R. Wischik C.M. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: A randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 2016 388 10062 2873 2884 10.1016/S0140‑6736(16)31275‑2 27863809
    [Google Scholar]
  28. Wilcock G.K. Gauthier S. Frisoni G.B. Jia J. Hardlund J.H. Moebius H.J. Bentham P. Kook K.A. Schelter B.O. Wischik D.J. Davis C.S. Staff R.T. Vuksanovic V. Ahearn T. Bracoud L. Shamsi K. Marek K. Seibyl J. Riedel G. Storey J.M.D. Harrington C.R. Wischik C.M. Potential of low dose leuco-methylthioninium bis(Hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer’s disease: Cohort analysis as modified primary outcome in a phase III clinical trial. J. Alzheimers Dis. 2017 61 1 435 457 10.3233/JAD‑170560 29154277
    [Google Scholar]
  29. McKhann G.M. Knopman D.S. Chertkow H. Hyman B.T. Jack C.R. Jr Kawas C.H. Klunk W.E. Koroshetz W.J. Manly J.J. Mayeux R. Mohs R.C. Morris J.C. Rossor M.N. Scheltens P. Carrillo M.C. Thies B. Weintraub S. Phelps C.H. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011 7 3 263 269 10.1016/j.jalz.2011.03.005 21514250
    [Google Scholar]
  30. Johnson L.A. Cushing B. Rohlfing G. Edwards M. Davenloo H. D’Agostino D. Hall J.R. O’Bryant S.E. The Hachinski Ischemic Scale and cognition: The influence of ethnicity. Age Ageing 2014 43 3 364 369 10.1093/ageing/aft189 24321843
    [Google Scholar]
  31. Tripathi S.M. Murray A.D. Wischik C.M. Schelter B. Crossed cerebellar diaschisis in Alzheimer’s disease. Nucl. Med. Commun. 2022 43 4 423 427 10.1097/MNM.0000000000001531 35081090
    [Google Scholar]
  32. Tripathi S.M. McNeil C.J. Staff R.T. Murray A.D. Wischik C.M. Schelter B. Waiter G.D. FDG-PET image classification in Alzheimer’s disease: From traditional visual analysis to advanced transfer learning. Nucl. Med. Mol. Imaging 2025 59 3 201 208 10.1007/s13139‑025‑00908‑2 40385367
    [Google Scholar]
  33. Fazekas F. Chawluk J.B. Alavi A. Hurtig H.I. Zimmerman R.A. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am. J. Roentgenol. 1987 149 2 351 356 10.2214/ajr.149.2.351 3496763
    [Google Scholar]
  34. Schmidt P. Gaser C. Arsic M. Buck D. Förschler A. Berthele A. Hoshi M. Ilg R. Schmid V.J. Zimmer C. Hemmer B. Mühlau M. An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. Neuroimage 2012 59 4 3774 3783 10.1016/j.neuroimage.2011.11.032 22119648
    [Google Scholar]
  35. de Sitter A. Steenwijk M.D. Ruet A. Versteeg A. Liu Y. van Schijndel R.A. Pouwels P.J.W. Kilsdonk I.D. Cover K.S. van Dijk B.W. Ropele S. Rocca M.A. Yiannakas M. Wattjes M.P. Damangir S. Frisoni G.B. Sastre-Garriga J. Rovira A. Enzinger C. Filippi M. Frederiksen J. Ciccarelli O. Kappos L. Barkhof F. Vrenken H. MAGNIMS study group and for neuGRID Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study. Neuroimage 2017 163 106 114 10.1016/j.neuroimage.2017.09.011 28899746
    [Google Scholar]
  36. Maldjian J.A. Whitlow C.T. Saha B.N. Kota G. Vandergriff C. Davenport E.M. Divers J. Freedman B.I. Bowden D.W. Automated white matter total lesion volume segmentation in diabetes. AJNR Am. J. Neuroradiol. 2013 34 12 2265 2270 10.3174/ajnr.A3590 23868156
    [Google Scholar]
  37. Waymont J.M.J. Petsa C. McNeil C.J. Murray A.D. Waiter G.D. Validation and comparison of two automated methods for quantifying brain white matter hyperintensities of presumed vascular origin. J. Int. Med. Res. 2019 48 2 300060519880053 10.1177/0300060519880053 31612759
    [Google Scholar]
  38. Sapkota S. Ramirez J. Yhap V. Masellis M. Black S.E. Alzheimer’s disease neuroimaging initiative Brain atrophy trajectories predict differential functional performance in Alzheimer’s disease: Moderations with apolipoprotein E and sex. Alzheimers Dement. 2021 13 1 e12244 10.1002/dad2.12244 34692981
    [Google Scholar]
  39. Prins N.D. Scheltens P. White matter hyperintensities, cognitive impairment and dementia: An update. Nat. Rev. Neurol. 2015 11 3 157 165 10.1038/nrneurol.2015.10 25686760
    [Google Scholar]
  40. Hu H.Y. Ou Y.N. Shen X.N. Qu Y. Ma Y.H. Wang Z.T. Dong Q. Tan L. Yu J.T. White matter hyperintensities and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 36 prospective studies. Neurosci. Biobehav. Rev. 2021 120 16 27 10.1016/j.neubiorev.2020.11.007 33188821
    [Google Scholar]
  41. Sierra C. Essential hypertension, cerebral white matter pathology and ischemic stroke. Curr. Med. Chem. 2014 21 19 2156 2164 10.2174/0929867321666131227155140 24372222
    [Google Scholar]
  42. Eglit G.M.L. Weigand A.J. Nation D.A. Bondi M.W. Bangen K.J. Hypertension and Alzheimer’s disease: Indirect effects through circle of Willis atherosclerosis. Brain Commun. 2020 2 2 fcaa114 10.1093/braincomms/fcaa114 33543127
    [Google Scholar]
  43. Faraco G. Iadecola C. Hypertension. Hypertension 2013 62 5 810 817 10.1161/HYPERTENSIONAHA.113.01063 23980072
    [Google Scholar]
  44. Santisteban M.M. Iadecola C. Carnevale D. Hypertension, neurovascular dysfunction, and cognitive impairment. Hypertension 2023 80 1 22 34 10.1161/HYPERTENSIONAHA.122.18085 36129176
    [Google Scholar]
  45. Yao Q. Jiang K. Lin F. Zhu T. Khan N.H. Jiang E. Pathophysiological association of Alzheimer’s disease and Hypertension: A clinical concern for elderly population. Clin. Interv. Aging 2023 18 713 728 10.2147/CIA.S400527 37181536
    [Google Scholar]
  46. Chui H.C. Zheng L. Reed B.R. Vinters H.V. Mack W.J. Vascular risk factors and Alzheimer’s disease: Are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review. Alzheimers Res. Ther. 2012 4 1 1 10.1186/alzrt98 22182734
    [Google Scholar]
  47. Ungvari Z. Toth P. Tarantini S. Prodan C.I. Sorond F. Merkely B. Csiszar A. Hypertension-induced cognitive impairment: From pathophysiology to public health. Nat. Rev. Nephrol. 2021 17 10 639 654 10.1038/s41581‑021‑00430‑6 34127835
    [Google Scholar]
  48. Steinman J. Sun H.S. Feng Z.P. Microvascular alterations in Alzheimer’s disease. Front. Cell. Neurosci. 2021 14 618986 10.3389/fncel.2020.618986 33536876
    [Google Scholar]
  49. Schäfer A. Chaggar P. Thompson T.B. Goriely A. Kuhl E. Predicting brain atrophy from tau pathology: A summary of clinical findings and their translation into personalized models. Brain Multiphys. 2021 2 100039 10.1016/j.brain.2021.100039
    [Google Scholar]
  50. Walker K.A. Power M.C. Gottesman R.F. Defining the relationship between Hypertension, cognitive decline, and Dementia: A review. Curr. Hypertens. Rep. 2017 19 3 24 10.1007/s11906‑017‑0724‑3 28299725
    [Google Scholar]
  51. Dickstein D.L. Walsh J. Brautigam H. Stockton S.D. Jr Gandy S. Hof P.R. Role of vascular risk factors and vascular dysfunction in Alzheimer’s disease. Mt. Sinai J. Med. 2010 77 1 82 102 10.1002/msj.20155 20101718
    [Google Scholar]
  52. Gottesman R.F. Schneider A.L.C. Albert M. Alonso A. Bandeen-Roche K. Coker L. Coresh J. Knopman D. Power M.C. Rawlings A. Sharrett A.R. Wruck L.M. Mosley T.H. Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. JAMA Neurol. 2014 71 10 1218 1227 10.1001/jamaneurol.2014.1646 25090106
    [Google Scholar]
  53. Parandiyal N Chutia P Sinha SS Pandit P Majrashi NA Qureshi N Tripathi SM Characteristics of hypertension and its impact on cognitive functions in older adults: A cross-sectional study. Front Dement 2024 3 1486147 10.3389/frdem.2024.1486147 39659659
    [Google Scholar]
  54. Sparks D.L. Scheff S.W. Liu H. Landers T.M. Coyne C.M. Hunsaker J.C. III Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J. Neurol. Sci. 1995 131 2 162 169 10.1016/0022‑510X(95)00105‑B 7595642
    [Google Scholar]
  55. Mosconi L. McHugh P.F. FDG- and amyloid-PET in Alzheimer’s disease: Is the whole greater than the sum of the parts? Q. J. Nucl. Med. Mol. Imaging 2011 55 3 250 264 21532539
    [Google Scholar]
  56. Jellinger K.A. Attems J. Prevalence of dementia disorders in the oldest-old: An autopsy study. Acta Neuropathol. 2010 119 4 421 433 10.1007/s00401‑010‑0654‑5 20204386
    [Google Scholar]
  57. Thal D.R. Attems J. Ewers M. Spreading of amyloid, tau, and microvascular pathology in Alzheimer’s disease: Findings from neuropathological and neuroimaging studies. J. Alzheimers Dis. 2014 42 s4 S421 S429 10.3233/JAD‑141461 25227313
    [Google Scholar]
  58. Ottoy J. Niemantsverdriet E. Verhaeghe J. De Roeck E. Struyfs H. Somers C. wyffels L. Ceyssens S. Van Mossevelde S. Van den Bossche T. Van Broeckhoven C. Ribbens A. Bjerke M. Stroobants S. Engelborghs S. Staelens S. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging. Neuroimage Clin. 2019 22 101771 10.1016/j.nicl.2019.101771 30927601
    [Google Scholar]
  59. Rice L. Bisdas S. The diagnostic value of FDG and amyloid PET in Alzheimer’s disease—A systematic review. Eur. J. Radiol. 2017 94 16 24 10.1016/j.ejrad.2017.07.014 28941755
    [Google Scholar]
  60. Jellinger K.A. Attems J. Challenges of multimorbidity of the aging brain: A critical update. J. Neural Transm. 2015 122 4 505 521 10.1007/s00702‑014‑1288‑x 25091618
    [Google Scholar]
  61. Attems J. Jellinger K.A. The overlap between vascular disease and Alzheimer’s disease - Lessons from pathology. BMC Med. 2014 12 1 206 10.1186/s12916‑014‑0206‑2 25385447
    [Google Scholar]
  62. Esiri M.M. Joachim C. Sloan C. Christie S. Agacinski G. Bridges L.R. Wilcock G.K. Smith A.D. Cerebral subcortical small vessel disease in subjects with pathologically confirmed Alzheimer disease: A clinicopathologic study in the Oxford Project to Investigate Memory and Ageing (OPTIMA). Alzheimer Dis. Assoc. Disord. 2014 28 1 30 35 10.1097/WAD.0b013e31829b72f1 23842286
    [Google Scholar]
  63. Zekry D. Duyckaerts C. Moulias R. Belmin J. Geoffre C. Herrmann F. Hauw J.J. Degenerative and vascular lesions of the brain have synergistic effects in dementia of the elderly. Acta Neuropathol. 2002 103 5 481 487 10.1007/s00401‑001‑0493‑5 11935264
    [Google Scholar]
  64. Marwarha G. Ghribi O. Does the oxysterol 27-hydroxycholesterol underlie Alzheimer’s disease–Parkinson’s disease overlap? Exp. Gerontol. 2015 68 13 18 10.1016/j.exger.2014.09.013 25261765
    [Google Scholar]
  65. Zhao X.S. Wu Q. Peng J. Pan L.H. Ren Z. Liu H.T. Jiang Z.S. Wang G.X. Tang Z.H. Liu L.S. Hyperlipidemia-induced apoptosis of hippocampal neurons in apoE(−/−) mice may be associated with increased PCSK9 expression. Mol. Med. Rep. 2017 15 2 712 718 10.3892/mmr.2016.6055 28000893
    [Google Scholar]
  66. Mielke M.M. Zandi P.P. Sjögren M. Gustafson D. Östling S. Steen B. Skoog I. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005 64 10 1689 1695 10.1212/01.WNL.0000161870.78572.A5 15911792
    [Google Scholar]
  67. Whitmer R.A. Sidney S. Selby J. Johnston S.C. Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005 64 2 277 281 10.1212/01.WNL.0000149519.47454.F2 15668425
    [Google Scholar]
  68. Solomon A. Kivipelto M. Wolozin B. Zhou J. Whitmer R.A. Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement. Geriatr. Cogn. Disord. 2009 28 1 75 80 10.1159/000231980 19648749
    [Google Scholar]
  69. Sano M. Bell K.L. Galasko D. Galvin J.E. Thomas R.G. van Dyck C.H. Aisen P.S. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011 77 6 556 563 10.1212/WNL.0b013e318228bf11 21795660
    [Google Scholar]
  70. Baglietto-Vargas D. Shi J. Yaeger D.M. Ager R. LaFerla F.M. Diabetes and Alzheimer’s disease crosstalk. Neurosci. Biobehav. Rev. 2016 64 272 287 10.1016/j.neubiorev.2016.03.005 26969101
    [Google Scholar]
  71. Luchsinger J.A. Reitz C. Honig L.S. Tang M.X. Shea S. Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005 65 4 545 551 10.1212/01.wnl.0000172914.08967.dc 16116114
    [Google Scholar]
  72. Ott A. Stolk R.P. Hofman A. van Harskamp F. Grobbee D.E. Breteler M.M.B. Association of Diabetes mellitus and Dementia: The Rotterdam study. Diabetologia 1996 39 11 1392 1397 10.1007/s001250050588 8933010
    [Google Scholar]
  73. Xu W. Caracciolo B. Wang H.X. Winblad B. Bäckman L. Qiu C. Fratiglioni L. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 2010 59 11 2928 2935 10.2337/db10‑0539 20713684
    [Google Scholar]
  74. Chatterjee S. Mudher A. Alzheimer’s Disease and type 2 Diabetes: A critical assessment of the shared pathological traits. Front. Neurosci. 2018 12 383 10.3389/fnins.2018.00383 29950970
    [Google Scholar]
  75. Femminella G.D. Bencivenga L. Petraglia L. Visaggi L. Gioia L. Grieco F.V. de Lucia C. Komici K. Corbi G. Edison P. Rengo G. Ferrara N. Antidiabetic drugs in Alzheimer’s disease: Mechanisms of action and future perspectives. J. Diabetes Res. 2017 2017 1 7 10.1155/2017/7420796 28656154
    [Google Scholar]
  76. Muñoz-Jiménez M. Zaarkti A. García-Arnés J.A. García-Casares N. Antidiabetic drugs in Alzheimer’s disease and mild cognitive impairment: A systematic review. Dement. Geriatr. Cogn. Disord. 2020 49 5 423 434 10.1159/000510677 33080602
    [Google Scholar]
  77. McKeith I.G. Galasko D. Kosaka K. Perry E.K. Dickson D.W. Hansen L.A. Salmon D.P. Lowe J. Mirra S.S. Byrne E.J. Lennox G. Quinn N.P. Edwardson J.A. Ince P.G. Bergeron C. Burns A. Miller B.L. Lovestone S. Collerton D. Jansen E.N.H. Ballard C. de Vos R.A.I. Wilcock G.K. Jellinger K.A. Perry R.H. Consensus guidelines for the clinical and pathologic diagnosis of Dementia with Lewy Bodies (DLB). Neurology 1996 47 5 1113 1124 10.1212/WNL.47.5.1113 8909416
    [Google Scholar]
  78. Zetterberg H. Blennow K. Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics. Mol. Neurodegener. 2021 16 1 10 10.1186/s13024‑021‑00430‑x 33608044
    [Google Scholar]
  79. Matthews F.E. Brayne C. Lowe J. McKeith I. Wharton S.B. Ince P. Epidemiological pathology of Dementia: Attributable-risks at death in the Medical Research Council cognitive function and ageing study. PLoS Med. 2009 6 11 e1000180 10.1371/journal.pmed.1000180 19901977
    [Google Scholar]
/content/journals/car/10.2174/0115672050399596251106033110
Loading
Hypertension is the Main Vascular Risk Factor for Cognitive Impairment, Microvascular Pathology and Brain Atrophy in Alzheimer’s Disease
Bentham Science Publishers ; https://doi.org/10.2174/0115672050399596251106033110
/content/journals/car/10.2174/0115672050399596251106033110
/content/journals/car/10.2174/0115672050399596251106033110
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: diabetes ; dyslipidemia ; Alzheimer’s disease ; FDG-PET ; brain atrophy ; hypertension

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test